1. Home
  2. PHGE vs PET Comparison

PHGE vs PET Comparison

Compare PHGE & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • PET
  • Stock Information
  • Founded
  • PHGE 2015
  • PET 2015
  • Country
  • PHGE Israel
  • PET United States
  • Employees
  • PHGE N/A
  • PET N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • PET EDP Services
  • Sector
  • PHGE Health Care
  • PET Technology
  • Exchange
  • PHGE Nasdaq
  • PET Nasdaq
  • Market Cap
  • PHGE 13.3M
  • PET 10.7M
  • IPO Year
  • PHGE N/A
  • PET N/A
  • Fundamental
  • Price
  • PHGE $0.96
  • PET $0.30
  • Analyst Decision
  • PHGE Strong Buy
  • PET Strong Buy
  • Analyst Count
  • PHGE 2
  • PET 5
  • Target Price
  • PHGE $13.50
  • PET $4.90
  • AVG Volume (30 Days)
  • PHGE 48.8K
  • PET 900.1K
  • Earning Date
  • PHGE 04-02-2025
  • PET 03-04-2025
  • Dividend Yield
  • PHGE N/A
  • PET N/A
  • EPS Growth
  • PHGE N/A
  • PET N/A
  • EPS
  • PHGE N/A
  • PET N/A
  • Revenue
  • PHGE N/A
  • PET $76,747,000.00
  • Revenue This Year
  • PHGE N/A
  • PET N/A
  • Revenue Next Year
  • PHGE N/A
  • PET $6.78
  • P/E Ratio
  • PHGE N/A
  • PET N/A
  • Revenue Growth
  • PHGE N/A
  • PET N/A
  • 52 Week Low
  • PHGE $0.48
  • PET $0.14
  • 52 Week High
  • PHGE $8.55
  • PET $2.47
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 65.22
  • PET 48.46
  • Support Level
  • PHGE $0.87
  • PET $0.29
  • Resistance Level
  • PHGE $0.99
  • PET $0.38
  • Average True Range (ATR)
  • PHGE 0.08
  • PET 0.05
  • MACD
  • PHGE 0.01
  • PET -0.00
  • Stochastic Oscillator
  • PHGE 89.20
  • PET 26.75

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About PET Wag! Group Co.

Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools, and pet wellness plans.

Share on Social Networks: